Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 188

Similar articles for PubMed (Select 20873965)

1.

The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.

Koessler J, Kobsar AL, Rajkovic MS, Schafer A, Flierl U, Pfoertsch S, Bauersachs J, Steigerwald U, Rechner AR, Walter U.

Platelets. 2011;22(1):20-7. doi: 10.3109/09537104.2010.514967. Epub 2010 Sep 27.

PMID:
20873965
2.

Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.

Kobsar AL, Koessler J, Rajkovic MS, Brunner KP, Steigerwald U, Walter U.

Platelets. 2010;21(2):112-6. doi: 10.3109/09537100903440937.

PMID:
20085435
3.

Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance.

Tsantes A, Ikonomidis I, Papadakis I, Kottaridi C, Tsante A, Kalamara E, Kardoulaki A, Kopterides P, Kapsimali V, Karakitsos P, Lekakis J, Travlou A.

Platelets. 2012;23(6):481-9. doi: 10.3109/09537104.2012.689037. Epub 2012 May 30.

PMID:
22646492
4.

A comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention.

Jang J, Lim J, Chang K, Kim Y, Kim M, Park HI, Kim J, Shin S.

J Clin Lab Anal. 2012 Jul;26(4):262-6. doi: 10.1002/jcla.21515.

PMID:
22811359
5.

Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.

El Ghannudi S, Ohlmann P, Meyer N, Wiesel ML, Radulescu B, Chauvin M, Bareiss P, Gachet C, Morel O.

JACC Cardiovasc Interv. 2010 Jun;3(6):648-56. doi: 10.1016/j.jcin.2010.03.003.

6.

[Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].

Morel O, Viellard C, Faure A, Jesel L, Ohlmann P, Desprez D, Chauvin M, Roul G, Grunebaum L, Bareiss P.

Ann Cardiol Angeiol (Paris). 2007 Jan;56(1):21-9. French.

PMID:
17343035
7.

Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.

Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C.

J Thromb Haemost. 2005 Jan;3(1):85-92.

PMID:
15634270
8.

Comparison of the VASP assay and platelet aggregometry in the evaluation of platelet P2Y12 receptor blockade.

Kuliczkowski W, Rychlik B, Chiżyński K, Watała C, Golański J.

Pol Arch Med Wewn. 2011 Apr;121(4):115-21.

9.

Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y.

Linnemann B, Schwonberg J, Rechner AR, Mani H, Lindhoff-Last E.

Ann Hematol. 2010 Jun;89(6):597-605. doi: 10.1007/s00277-009-0881-9. Epub 2010 Jan 5.

PMID:
20049442
10.

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.

Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ.

Thromb Haemost. 2008 Jan;99(1):215-22. doi: 10.1160/TH07-09-0555.

PMID:
18217157
11.
12.

Usefulness of the INNOVANCE PFA P2Y test cartridge for the detection of patients with congenital defects of the platelet P2Y₁₂ receptor for adenosine diphosphate.

Scavone M, Germanovich K, Femia EA, Cattaneo M.

Thromb Res. 2014 Feb;133(2):254-6. doi: 10.1016/j.thromres.2013.11.022. Epub 2013 Dec 1.

PMID:
24331208
13.

Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials.

Lemesle G, Landel JB, Bauters A, Delhaye C, Bonello L, Sudre A, Susen S, Bauters C, Lablanche JM.

Platelets. 2014;25(7):499-505. doi: 10.3109/09537104.2013.840363. Epub 2013 Oct 31.

PMID:
24176022
14.

Ability of the INNOVANCE PFA P2Y system to detect clopidogrel-induced ADP receptor blockade in preangiocath individuals.

McGlasson DL, Shah AD, Fritsma GA.

Blood Coagul Fibrinolysis. 2011 Oct;22(7):583-7. doi: 10.1097/MBC.0b013e328349a2ba.

PMID:
21799401
15.

The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.

Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF.

Platelets. 2008 Mar;19(2):125-33. doi: 10.1080/09537100701694144.

PMID:
18297550
16.

Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.

Aradi D, Magyarlaki T, Tokés-Füzesi M, Rideg O, Vorobcsuk A, Komócsi A.

Platelets. 2010;21(7):563-70. doi: 10.3109/09537104.2010.494742.

PMID:
20642320
18.

Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.

Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, Barragan P, Camoin-Jau L.

J Thromb Haemost. 2007 Aug;5(8):1630-6. Epub 2007 May 7.

PMID:
17488353
19.

Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.

Lepäntalo A, Virtanen KS, Reséndiz JC, Mikkelsson J, Viiri LE, Karhunen PJ, Lassila R.

Thromb Res. 2009 Jun;124(2):193-8. doi: 10.1016/j.thromres.2009.01.009. Epub 2009 Feb 15.

PMID:
19232433
20.

Evaluation of the new INNOVANCE® PFA P2Y cartridge in patients with impaired primary haemostasis.

Koessler J, Ehrenschwender M, Kobsar A, Brunner K.

Platelets. 2012;23(8):571-8. doi: 10.3109/09537104.2011.640967. Epub 2011 Dec 20.

PMID:
22185369
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk